ライフサイエンスコーパス: lowering

1 over limiting reductive elimination via LUMO lowering.

2 lesion regression following aggressive lipid lowering.

3 efficacy of different dietary patterns on BP lowering.

4 be more relevant than whether to start lipid lowering.

5 ts of wtHTT loss following non-selective HTT lowering.

6 n B antisense oligonucleotide-mediated lipid lowering.

7 that decreasing lipid unsaturation levels by lowering 18:3 fatty-acid amount through reducing FAD3 ex

8 e the C4-functionalized 1,4-dihydropyridine, lowering a second barrier that would otherwise prohibit

9 Lowering Abeta42 reversed the DIO deficit in the eNOS/cG

10 SGLT2i, possibly compromising their glucose-lowering ability.

11 he disease achieving an intraocular pressure-lowering action comparable to the clinically used dorzol

12 tributions of polyphenols to the cholesterol-lowering actions of lupins.

13 d a phantom study to determine the impact of lowering administered activity on image noise, finding t

14 Associations between IOP lowering after CE and biometric parameters may allow for

15 t implant were noninferior to timolol in IOP lowering after each administration.

16 Fenofibrate, a PPARalpha agonist and lipid-lowering agent, decreases amputation incidence in patien

17 List prices of lipid-lowering agents (n = 11) increased by 278% and net price

18 The emergence of new glucose-lowering agents - sodium-glucose cotransporter 2 inhibit

19 diabetes and are the newest class of glucose-lowering agents approved in the United States.

20 ater use of drop-in cardioprotective glucose-lowering agents demonstrated blunting of signal detectio

21 ing cardiovascular outcome trials of glucose-lowering agents under the premise of glycemic equipoise.

22 c inflammation due to their pleotropic lipid lowering and anti-inflammatory properties.

23 These results support ASO-mediated PrP lowering, and PrP-lowering therapeutics in general, as a

24 apeutically, the first human trial of an HTT-lowering antisense oligonucleotide successfully, and saf

25 ed the absolute and relative impact of lipid lowering as a function of age, age at initiation, and no

26 kers can be reversed by a single dose of PrP-lowering ASO administered after the detection of patholo

27 CEL (Exenatide Study of Cardiovascular Event Lowering) assessed the impact of once-weekly exenatide 2

28 Evolocumab is an effective therapy for lowering atherogenic lipoproteins in PLHIV with high car

29 ctiveness of the electron transport chain by lowering ATP and increasing ROS productions.

30 t DNMT1 RFTS mutations deregulate metabolism lowering ATP levels, as a result of increased purine cat

31 Also, lowering ATXN2 expression in TDP-43 ALS mice prolongs th

32 mice with an antisense oligonucleotide (ASO) lowering ATXN2 expression.

33 of acetylation in vitro, and is effective at lowering bacterial load in a mouse model of infection.

34 This could reduce RBD presentation on virus, lowering binding to host ACE2 and decreasing viral entry

35 gptl3 would improve cardiovascular health by lowering blood cholesterol and triglycerides, the lipoMS

36 ve some aspects of cardiometabolic health by lowering blood pressure and insulin resistance.

37 However, interventions such as lowering blood pressure, smoking cessation, and lifestyl

38 Lowering blood sugar by the sodium-glucose co-transporte

39 The 2 major factors lowering BP in tilt-induced vasovagal syncope were reduc

40 scued kidney injury in knockout mice without lowering BP.

41 remature deaths of APP/PS1-Tg mice at a dose lowering brain 24S-hydroxycholesterol by approximately 5

42 y of dietary patterns on blood pressure (BP) lowering but their findings are largely conflicting.

43 ive lowering was favored over less-intensive lowering, but the data were less clear for patients with

44 Delaying lipid lowering by 10 years (treatment for 20 years) would resu

45 Lipoprotein(a) lowering by alirocumab is an independent contributor to

46 The G6P lowering by metformin was mimicked by a complex 1 inhibi

47 Pharmacologic and genetic approaches lowering calpain activity showed beneficial effects on m

48 ial clinical impact of strategies focused on lowering cancer risk by preventing premature aging or pr

49 ity of developing immune-based therapies for lowering cardiovascular risk.

50 of TIZ points towards its overall effect in lowering cell metabolism and RNA processing and modifica

51 irculation, have been considered targets for lowering cholesterol.

52 ional theory calculations herein reveal that lowering *CO(2) coverage on the Cu surface decreases the

53 st FDC maintained statistically superior IOP lowering compared to its components at every assessment

54 s a possible therapeutic use for cholesterol lowering compounds in reducing Alternaria-stimulated all

55 e, suggests the possibility that cholesterol lowering compounds may be beneficial in alleviating alle

56 restrictions appear to be most effective at lowering COVID-19 cases, while border closures appear to

57 to destabilize Hb-heme interactions, thereby lowering DeltaH(*), while contacts from the N3 subsite p

58 A promising strategy to lowering detection limits in electrochemical analysis is

59 IOP-lowering drops were prescribed for 30 cases (7.2%).

60 id not suggest that the use of related lipid-lowering drug classes would affect AD risk.

61 he protein targets of several approved lipid-lowering drug classes: HMGCR (encoding the target for st

62 Increasing evidence suggest that the glucose-lowering drug metformin exerts a valuable anti-senescenc

63 Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatmen

64 ardiovascular outcomes of an LDL cholesterol-lowering drug recommended by the 2018 American College o

65 As IDOL is a putative lipid-lowering drug target, we investigated the molecular deta

66 indexed expected effects of modulating lipid-lowering drug targets on PD.

67 utive HbA1c >=8.5% while on >=2 oral glucose-lowering drugs (OGLDs), with validation in another multi

68 diseases in 3 populations (Genetics of Lipid Lowering Drugs and Diet Network, n = 978; Framingham Hea

69 s suffering from POAG, IOP and number of IOP-lowering drugs applied can be effectively reduced by XEN

70 as defined as prescription of blood pressure-lowering drugs as obtained from the national drug regist

71 Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review

72 udy the cardiovascular safety of new glucose-lowering drugs have improved our understanding of type 2

73 Long-term exposure to lipid-lowering drugs might affect Parkinson's disease (PD) ris

74 hibitors (SGLT2i) are a new class of glucose-lowering drugs that act primarily in the kidney, but som

75 0 mmol/mol) on a maximum of two oral glucose-lowering drugs with or without basal insulin, and a body

76 comprising statins, multiple blood-pressure-lowering drugs, and aspirin has been proposed to reduce

77 P), the active substances of the applied IOP-lowering drugs, the best corrected visual acuity (BCVA)

78 s disease of users of any other oral glucose lowering drugs.

79 y replaces SFA, the greatest LDL-cholesterol-lowering effect is seen with PUFA, followed by MUFA, and

80 The hepatic lipid-lowering effect observed in animals cotreated with VPA a

81 Leptin mediated the glucose-lowering effect of early-life nutrition in women but not

82 The ALT-lowering effect of rs72613567:TA was amplified by increa

83 r and how glucagon may influence the glucose-lowering effect of SGLT2 inhibition, we subjected 12 pat

84 w a clinically significant difference in IOP-lowering effect or tolerability.

85 ProINS-Tf also demonstrated a better glucose-lowering effect than native insulin, even with a much lo

86 0.5) ~ 18 h), has significant blood-pressure lowering effect, and shows fast recovery of heart functi

87 aucoma medication was prescribed with a good lowering effect.

88 ems to have no negative influence on the IOP lowering-effect of iStent inject(R) implantation in pati

89 The study analyzed whether the BP-lowering effects of sacubitril/valsartan accounted for i

90 t effect of sacubitril/valsartan, and the BP-lowering effects of sacubitril/valsartan did not account

91 diabetes and obesity but have limited weight-lowering efficacy and minimal insulin sensitizing action

92 oof-of-principle data for its blood pressure-lowering efficacy.

93 be set up with little coding required, thus lowering entry barriers to new users.

94 ystem reduces its learning rate by virtue of lowering error sensitivity when faced with uncertainty.

95 nd personalizes immunosuppressive therapy by lowering exposure to immunosuppressive drugs, likely res

96 Lowering external costs with fleet electrification, howe

97 The benefit of blood pressure lowering for the prevention of dementia or cognitive imp

98 n effective with continued administration in lowering fracture risk.

99 Lowering high blood pressure with specific antihypertens

100 Lowering hyperglycemia is the typical therapeutic goal i

101 ions of supercompatibility can be useful for lowering hysteresis, but with limitations for systems wi

102 Immediate initiation of lipid lowering (ie, treatment for 30 years) in 40- to 49-year-

103 e-glutathione cycle and nutrient uptake, and lowering in oxidative stress.

104 nt clinical literature supports intensive BP lowering in patients with hypertension for improving car

105 BEIJERINCK (EvolocumaB Effect on LDL-C Lowering in SubJEcts with Human Immunodeficiency VirRus

106 he iStent to CE improved the duration of IOP lowering in White patients, but not in non-White patient

107 y thus represent one preventive strategy for lowering inflammatory status and thus atherosclerosis ri

108 AFFF formulations were less efficient at lowering interfacial tension than PFOA, FPOS, or FOSA su

109 of pharmacologic or strategy-driven glucose-lowering interventions for adults with type 2 diabetes f

110 es the activity of L-type Ca(V)1.2 channels, lowering intracellular Ca(2+) ([Ca(2+)](i)) and causing

111 ionine metabolism in CD8(+) T cells, thereby lowering intracellular levels of methionine and the meth

112 Its management currently focuses on lowering intraocular pressure to slow disease progressio

113 Both procedures are efficacious in lowering IOP in PACG, but the rate of complication and i

114 tion was similar to application by sponge in lowering IOP in patients with glaucoma and the safety of

115 cterized by death of retinal ganglion cells; lowering IOP is the only proven treatment strategy to de

116 to moderate POAG is safe, more effective in lowering IOP with fewer medications, and less likely to

117 The MGI was noninferior to the BGI in lowering IOP.

118 ed the eGI, increasing it for 'KDML105', and lowering it for 'CN1'.

119 ctrostatic screening of the exciton, in turn lowering its binding energy relative to the undoped pero

120 ms underlying ALS, potential consequences of lowering levels of gene products, and the need to consid

121 vo mouse model of human psoriasis while also lowering levels of pro-inflammatory cytokines in tissue

122 ty and reproducibility of culture systems by lowering lot-to-lot variations and the risk of contamina

123 Lowering low-density lipoprotein (LDL-C) and triglycerid

124 nized as critical not only for their role in lowering lung surface tension but also in innate host de

125 Cholesterol lowering may also have beneficial effects in sickle cell

126 ve pharmacotherapies, such as aspirin, lipid-lowering mediations, and cardiometabolic agents.

127 viation (P = 1.00), or concurrent use of IOP-lowering medication (P = 0.52).

128 Effects of phosphate-lowering medication on vascular calcification and arteri

129 Among other factors, age and urate-lowering medication were associated with alpha- and beta

130 y glaucoma severity or concurrent use of IOP-lowering medication.

131 (17.9%), antidepressants (17.8%), and lipid-lowering medications (16.5%).

132 41.1% vs 26.0%, P < 0.0001), and cholesterol-lowering medications (40.1% vs 27.8%, P = 0.0016) when c

133 participants without changes in cholesterol-lowering medications (n = 114), plasma surrogate cholest

134 All eyes were washed out of IOP-lowering medications before surgery and remained unmedic

135 ut no detectable difference in the use of BP-lowering medications between groups (OR 1.2, 95% CI 0.8-

136 After surgery, IOP and the number of IOP-lowering medications decreased significantly by 42.3% (P

137 was successfully managed with additional IOP-lowering medications in a majority of cases and did not

138 iated with migraine and the mechanisms of BP-lowering medications in migraine prophylaxis are unknown

139 ently, greater drop-in of open-label glucose-lowering medications occurred in the placebo group.

140 No differences in average number of pressure-lowering medications were detected between groups.

141 Association of glucose-lowering medications with cardiovascular outcomes: an um

142 ative time, postoperative IOP, number of IOP-lowering medications, and visual acuity (VA).

143 outcome measures included the number of IOP-lowering medications, bleb morphology using the Indiana

144 2 diabetes and variable response to glucose lowering medications, current evidence on optimal treatm

145 th participants not treated with cholesterol-lowering medications, those who were treated exhibited a

146 onsible for the diabetogenic effect of LDL-C-lowering medications.

147 y of SLT may predict reduced response to IOP lowering medications.

148 using compared with those using cholesterol-lowering medications.

149 ially to help guide the selection of glucose-lowering medications.

150 ostoperative IOP and requirement of pressure-lowering medications.

151 eting cystine import with an xCT transporter-lowering MEK inhibitor, in combination with statins, cau

152 or many, the question of when to start lipid lowering might be more relevant than whether to start li

153 hat excessive diastolic blood pressure (DBP) lowering might increase the risk of myocardial infarctio

154 The effect of blood pressure lowering might not be evident in specific domains of cog

155 e been treated by nonspecific immunoglobulin-lowering/modulating therapies, including immunoadsorptio

156 gy for the treatment of HD by simultaneously lowering mutant HTT levels and blocking its aggregation.

157 We propose lowering neuronal mitochondrial Ca(2+) by inhibiting the

158 nds were observed for D. flos-aquae and only lowering nitrogen decreased cyanopeptide production whil

159 a 70% qualified success rate with a mean IOP lowering of 25% (95% confidence interval [CI], 13.8%-36.

160 induction was associated with a significant lowering of ACR risk, particularly during the early post

161 ith an adjusted R(2) of 0.53 (P < 0.001) and lowering of BIC by 583.

162 in fruits and vegetables is associated with lowering of blood pressure (BP), but the nutrient(s) res

163 sfer coupling and thereby contributes to the lowering of charge-transfer-mediated coupling even at sh

164 eneficial effects are partly mediated by the lowering of core body temperature that occurs during CR.

165 mperometric assays of the films revealed the lowering of enzymatic activity of all four oxidases by C

166 cA with HF subtypes, and whether therapeutic lowering of GlycA can prevent HFpEF development.

167 This land-cover change generally involves lowering of groundwater level (GWL), as well as modifica

168 oelectric phase transformations identify the lowering of hysteresis and cyclic reversibility of the t

169 h higher baseline IOP may experience greater lowering of IOP after SLT.

170 LB was associated with significant lowering of median pain scale at 6 hours (1.0 [0-2.0] ve

171 The NLK-mediated lowering of mHTT is associated with enhanced phosphoryla

172 -clinical or MCI stage of AD and therapeutic lowering of neurotoxic peptide levels may delay progress

173 e combined contribution of FA and FA-induced lowering of pH), as well as a robust correlation between

174 Lowering of prion protein (PrP) expression in the brain

175 This lowering of sIgA yielded a large effect size in older in

176 Lowering of the electron kinetic energy (KE) upon initia

177 This lowering of the energy required for membrane deformation

178 esence of the ice-water interface leads to a lowering of the free-energy barrier for unfolding, resul

179 Lowering of the serum urate level with allopurinol may s

180 specific asymmetric anion positioning on the lowering of the symmetry.

181 Lowering or removal of calpain-1 in cells or mice counte

182 tril/valsartan on outcomes are related to BP lowering, particularly among women who derive greater be

183 al therapy is the mainstay of HIV treatment, lowering plasma viral levels below detection.

184 ession on erythroid precursor cells, thereby lowering potentially toxic-free intracellular iron level

185 n or >=1 medication reduction without an IOP lowering procedure.

186 have been suggested to possess blood glucose lowering properties by inhibiting sugar transporters in

187 No IOP-lowering prophylaxis was used postoperatively.

188 Lipid-lowering recommendations for prevention of atherosclerot

189 terol, and the evidence that LDL-cholesterol lowering reduces CVD incidence.

190 drug class was more effective than others in lowering risk of dementia.

191 ansport activity of ATP13A2 was required for lowering rotenone/DFMO-induced MitoROS, whereas exogenou

192 reduces anemia-dependent c-Kit signaling by lowering SAMD14 levels, we developed a genetic rescue as

193 m, breastmilk, and other tissues, capable of lowering serum thyroxine (T4) in rats.

194 In summary, the glucose-lowering SGLT2 inhibitor empagliflozin, used for type 2

195 LDL cholesterol lowering significantly reduced the risk of major vascula

196 helial-mesenchymal transition by cholesterol-lowering statins may promote the basal type of PDAC, con

197 g enzyme Nsdhl or treatment with cholesterol-lowering statins switches glandular pancreatic carcinoma

198 Beyond lipid-lowering, statins exert cardioprotective effects.

199 rol's impact on human health and cholesterol-lowering strategies.

200 quired glaucoma surgery with 2.2 +/- 1.2 IOP-lowering surgeries per eye.

201 ed with the sham-treated group underwent IOP-lowering surgery (5.7% vs. 11.9%).

202 onth 3, or (3) performance of additional IOP-lowering surgery before postoperative month 3.

203 re (IOP) of 5-20 mm Hg and no additional IOP-lowering surgery.

204 mpared intensive versus standard systolic BP lowering (targeting <120 mm Hg versus <140 mm Hg, respec

205 eral fiscal and policy interventions such as lowering tax and giving rebates to encourage parents to

206 microtubules in living cells and found that lowering temperature from 37 degrees C to 10 degrees C d

207 Lowering temperature to 140 degrees C while extending th

208 Hence, we propose that lowering the activation barrier for complexation is not

209 d across the IDL is destroyed, substantially lowering the adhesion in a reversible fashion.

210 ll until transcriptional controls succeed in lowering the amount of the importer.

211 desorption and promoting C(2) production by lowering the apparent barrier for CO dimerization.

212 f calcium flux in the Xenopus laevis embryo, lowering the barrier for in vivo physiology work in this

213 Our results indicate that lowering the catalytic activity of Vav2 below specific t

214 Furthermore, lowering the charge state consequently increases the mas

215 in limiting environmental AMR dissemination, lowering the community-level burden of antimicrobial-res

216 d annealing, this is achieved by raising and lowering the concentration of a multi-role reagent to ef

217 after iodine-based contrast administration, lowering the cutoff for administering prophylaxis to glo

218 und and chilling treatment strongly promoted lowering the eGI of both rice cultivars.

219 than required for the electrochemical step, lowering the electrochemical barrier, and hydrogen bondi

220 sition-metal coordination as responsible for lowering the energetic barrier to ring closure.

221 ) and H(2) O precursors simultaneously, thus lowering the energy barriers of CO(2) electroreduction.

222 imvastatin) blocked ATP and IL-33 release by lowering the expression of VDAC-1 in the plasma membrane

223 Here, the effects of lowering the expression of wild-type (wt)HTT on the func

224 ssess the metabolic consequences of directly lowering the hepatic cytosolic NADH/NAD(+) ratio in mice

225 es a unique advantage to the PCET process by lowering the inner-sphere reorganization energy by limit

226 achieved by a strong albumin binding, and by lowering the insulin receptor affinity 500-fold to slow

227 t attenuates it for high-risk individuals by lowering the overall prevalence of the virus in the soci

228 the reliance on high-power gradient drivers, lowering the overall requirements for power and cooling,

229 agreement to agreement equal to chance while lowering the percent agreement by 10%.

230 cleosomes act as obstacles to the diffusion, lowering the permeability and hence reducing the effecti

231 gher bacterial inoculum (10(7) CFU/mL) or by lowering the pH in standard media to simulate the enviro

232 It is observed that lowering the pH in the physiological range (7.4-7.2) res

233 ws synaptic depression, which is achieved by lowering the probability of vesicle release, promoting e

234 able via a reduction in diffusivity-i.e., by lowering the rate at which neuronal fluctuations dispers

235 unced selectivity can be further enhanced by lowering the reaction temperature or decreasing the solv

236 tree) at a higher cell division resolution (lowering the required number of cell division difference

237 ore prevents rapid outgassing by effectively lowering the resultant pressure gradient across the poly

238 into microbiome-directed strategies aimed at lowering the risk for autoimmune disease and underscorin

239 et revealed a significant effect of high SBP lowering the risk of AD (beta(GSMR) = -0.19, p = .04).

240 tential long-term benefits of PUFA intake in lowering the risk of CVD and premature death.

241 an adequate magnesium intake is essential in lowering the risk of mortality in CRC patients, yet the

242 s means screening fewer individuals, thereby lowering the statistical precision of prevalence estimat

243 ons then emanate from these sites with time, lowering the stress while bending the beam plastically.

244 using standardized house dust mite extract, lowering the target dose at the end of the rush phase an

245 Lowering the temperature slowed down endocytosis, thereb

246 Neither lowering the test concentration, nor incorporation of ne

247 eract the negative effects of ATP binding by lowering the threshold for RAF dimerization and pathway

248 o(II) centre accelerates carbonate attack by lowering the transition state enthalpy.

249 s support ASO-mediated PrP lowering, and PrP-lowering therapeutics in general, as a promising path fo

250 d interpret pharmacodynamic readouts for HTT lowering therapeutics.

251 ed potential eligibility for intensive lipid-lowering therapies (very high risk) under the 2018 AHA/A

252 nger durations, considering studying glucose-lowering therapies as first-line management of type 2 di

253 ple risk enhancers and novel intensive lipid-lowering therapies for secondary prevention.

254 to summarise the evidence of LDL cholesterol lowering therapies in older patients.

255 ure the cardiovascular safety of new glucose-lowering therapies to treat patients with type 2 diabete

256 Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout.

257 Glucose-lowering therapies were granted regulatory approval prim

258 ideline recommendations for the use of lipid-lowering therapies, including non-statin treatment, in o

259 infarction, associated with certain glucose-lowering therapies, the US Food and Drug Administration

260 ovascular protection indications for glucose-lowering therapies.

261 ria for intensive secondary prevention lipid-lowering therapy (28.3% vs. 40.0% vs. 81.4%, respectivel

262 resence of remission: (1) absence of glucose-lowering therapy (GLT); (2) normoglycaemia; and (3) for

263 ous coronary intervention to intensive lipid-lowering therapy (ILLT) comprising single LDL apheresis

264 thors examined 25,480 subjects free of lipid-lowering therapy and myocardial infarction at study entr

265 e HeFH >=12 years of age and on stable lipid-lowering therapy began subcutaneous evolocumab 420 mg mo

266 of initiation and intensification of glucose-lowering therapy in individuals newly diagnosed with T2D

267 is because guidelines do not recommend lipid-lowering therapy in such patients who do not have anothe

268 te initiation and intensification of glucose-lowering therapy is key to reducing the risk of major va

269 ference of intensive versus standard glucose-lowering therapy on risk of CVD events in the ACCORD (Ac

270 lesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of e

271 ns were extracted and categorised by glucose-lowering therapy, glycaemic thresholds, and duration.

272 esterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL

273 receipt of maximum doses of background lipid-lowering therapy.

274 ey are induced in the periphery during lipid-lowering therapy.

275 g families and healthcare professionals, and lowering thresholds for genetic counseling.

276 equences for therapeutic strategies aimed at lowering TMEM106B levels.

277 l function of TMEM106B and determine whether lowering TMEM106B may be a viable therapeutic strategy,

278 Lowering to 4 degrees C caused rapid loss of almost all

279 Low-strength evidence supported intensive lowering to a 10-mm Hg reduction in SBP for cardiovascul

280 on of alphaS aggregates while simultaneously lowering toxicity.

281 Intensive BP-lowering treatment decreases risk for OH.

282 7 years of age who had received stable lipid-lowering treatment for at least 4 weeks before screening

283 The clinical benefit of LDL cholesterol lowering treatment in older patients remains debated.

284 humans that may not require any proteinuria-lowering treatment or renal biopsy.FUNDINGATIP-Avenir pr

285 , age 30 to 59 years, not eligible for lipid-lowering treatment recommendation under the most recent

286 Although intensive blood pressure (BP)-lowering treatment reduces risk for cardiovascular disea

287 gene regions representing alternative lipid-lowering treatment targets (PCSK9, LDLR, NPC1L1, APOC3,

288 isease and a high risk of progression, urate-lowering treatment with allopurinol did not slow the dec

289 t statins reduce cancer risk but other lipid-lowering treatments do not.

290 Along with effective lipid-lowering treatments, the recent success of clinical tria

291 ng renal biopsies and the use of proteinuria-lowering treatments.

292 and represents a promising new approach for lowering triglycerides in patients with familial chylomi

293 flict, which, in turn, is a dispersion force lowering urbanization and the incentives to move to big

294 In contrast, evidence for the efficacy of BP lowering using the Mediterranean, vegetarian, Paleolithi

295 In most subpopulations, intensive lowering was favored over less-intensive lowering, but t

296 Blood pressure lowering was not significantly associated with a change

297 icant weight loss over a sham procedure.(The Lowering Weight in Severe Obesity by Embolization of the

298 lerability and efficacy of non-selective HTT lowering with an AAV5 encoded miRNA targeting human HTT

299 Blood pressure lowering with antihypertensive agents compared with cont

300 f randomized clinical trials, blood pressure lowering with antihypertensive agents compared with cont